|Bid||235.00 x 1200|
|Ask||246.15 x 1100|
|Day's Range||236.25 - 245.96|
|52 Week Range||208.35 - 526.00|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||39.86|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Illumina (ILMN) subsidiary GRAIL's MCED blood test will be offered along with existing single cancer screenings to advance cancer care delivery through early detection.
With its stock down 31% over the past month, it is easy to disregard Illumina (NASDAQ:ILMN). We, however decided to...
A Delaware jury on Friday ordered Illumina Inc to pay more than $333 million to a U.S. unit of Chinese genomics company BGI Group after finding that Illumina's DNA-sequencing systems infringed two patents. The jury also said Illumina infringed the patents willfully, and that three patents it had accused BGI's Complete Genomics unit of infringing were invalid.